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Abstract
Background: Administration of a recombinant peptide of Periostin (rPN) has recently been shown to stimulate
cardiomyocyte proliferation and angiogensis after myocardial infarction (MI) [1]. However, strategies for targeting the
delivery of rPN to the heart are lacking. Intrapericardial administration of drug-eluting hydrogels may provide a clinically
viable strategy for increasing myocardial retention, therapeutic efficacy, and bioactivity of rPN and to decrease systemic re-
circulation.
Methods and Results: We investigated the ability of intrapericardial injections of drug-eluting hydrogels to deliver and
prolong the release of rPN to the myocardium in a large animal model of myocardial infarction. Gelfoam is an FDA-approved
hemostatic material commonly used in surgery, and is known to stimulate fibrin clot formation. We show that Gelfoam disks
loaded with rPN, when implanted within the pericardium or peritoneum of mammals becomes encapsulated within a non-
fibrotic fibrin-rich hydrogel, prolonging the in vitro and in vivo release of rPN. Administration into the pericardial cavity of
pigs, following a complete occlusion of the left anterior descending artery, leads to greater induction of cardiomyocyte
mitosis, increased cardiomyocyte cell cycle activity, and enhanced angiogenesis compared to direct injection of rPN alone.
Conclusions: The results of this study suggest that intrapericardial drug delivery of Gelfoam, enhanced by triggered clot
formation, can be used to effectively deliver rPN to the myocardium in a clinically relevant model of myocardial infarction.
The work presented here should enhance the translational potential of pharmaceutical-based strategies that must be
targeted to the myocardium.
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Introduction
Myocardial infarction (MI) results in the irreversible damage of
cardiac muscle, which ultimately leads to heart failure. Current
clinical strategies are mainly focused on attenuating the progres-
sive deterioration of the remaining viable myocardium [2].
Recently, however, there has been a paradigm shift toward
strategies aimed at regenerating the myocardium to improve
cardiac function [1,3,4]. One such approach involves the
administration of pharmaceuticals capable of either replacing lost
cardiomyocytes by stimulating recruitment and differentiation of
resident cardiac stem cells [5] or by enhancing the proliferation of
endogenous cardiomyocytes [1,3].
We have recently demonstrated that administration of a
recombinant truncated peptide of periostin (referred to as rPN
throughout this manuscript) in rats after MI increased cardiomy-
ocyte mitosis, improved ventricular remodeling and myocardial
function, reduced fibrosis and infarct size, and increased
angiogenesis [1]. Full length periostin is a matricellular protein
that consists of an N-terminal domain, tandem repeats of four
fasciclin I domains, and an alternatively spliced C-terminal region
[6]. In the developing heart, periostin is expressed in the
atrioventricular cushions and in the myocardium. However, in
the adult heart, expression is reduced to very low levels [6–12], but
is re-expressed after MI, where it plays a role in the maturation of
the infarct scar [8,9].
Use of rPN for the treatment of heart disease in humans would
require a system that permits the effective and targeted delivery to
the myocardium. The most commonly employed strategies for
delivering factors to the heart, which includes systemic, intracor-
onary, and intramyocardial injections, are of limited utility due to
the low solubility of rPN at therapeutically relevant concentrations.
In addition, without a tailored delivery vehicle, these approaches
have very poor specificity for the myocardium, necessitating
relatively large doses and increasing the potential for adverse
reactions in neighboring normal tissue.
Alternate, clinically relevant strategies that enable targeted
delivery to the heart and that minimize systemic circulation are
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eluting devices into the pericardial cavity (i.e. the virtual space
between the parietal pericardium and visceral layer). Previous
studies in chronically ischemic pigs have shown that direct
intrapericardial injection of growth factors resulted in increased
myocardial deposition and retention and decreased systemic
recirculation, compared to intracoronary or intravenous delivery
[13]. Implantation of a drug-eluting device within the pericardial
cavity might offer several advantages to direct injections, including
sustained spatio-temporal delivery of multiple factors over multiple
time scales, reduced proteolytic degradation (especially after MI),
and enhanced myocardial retention [14].
Gelfoam is an FDA-approved hemostatic medical device
prepared from purified pork skin gelatin USP granules and
crosslinked by a thermal treatment method [15]. It is water-
insoluble, bioresorbable, inexpensive, non-allergenic, and is able to
absorb and hold within its interstices many times its weight of
blood and other fluids. Gelfoam can be milled and easily injected
through a 5Fr catheter, which is necessary for intrapericardial
injections. Recently, Gelfoam disks loaded with mesenchymal stem
cells were injected into the pericardial cavity of pigs [16]. The
procedure was performed using minimally invasive techniques,
and the presence of Gelfoam in the pericardial cavity was not
associated with cardiac effusions or adhesions, suggesting that this
approach is clinically viable. Gelfoam disks have also been utilized
as a drug delivery vehicle [15,17–21]. However, the use of
Gelfoam to deliver therapeutics has been hindered by poor release
kinetics [15,17–21]. The addition of retardants such as polyeth-
ylene glycol 400 monostearate, cetyl ester wax, and collagen
hydrogels have been shown to prolong the drug release [15,22].
Interestingly, Gelfoam stimulates the clotting cascade in which
fibrin becomes deposited within the intersitital pores of the disk.
We hypothesized that intrapericardial injection of Gelfoam,
loaded with rPN, into the pericardial cavity would stimulate
spontaneous in vivo fibrin-hydrogel formation and enable the
prolonged release of rPN to the myocardium following MI.
In the present paper, we characterize the in vitro and in vivo drug
delivery of rPN from Gelfoam disks. We demonstrate that
Gelfoam disks become encased within fibrin-rich hydrogels when
implanted in the pericardial or peritoneal fluid of pigs or mice,
respectively. We show that Gelfoam-induced fibrin hydrogels
enable the prolonged release of rPN in vitro and within the
peritoneal cavity of mice, in vivo. We also demonstrate that
administration of Gelfoam disks loaded with rPN into the
pericardial cavity of pigs, following a complete occlusion of the
left anterior descending artery, leads to increased cardiomyocyte
cell cycle activity and angiogenesis, compared to direct injection of
rPN alone.
Results
Gelfoam disks become encapsulated within a fibrin
matrix after peritoneal implantation in mice
We hypothesized that Gelfoam’s innate ability to stimulate in
vivo clot formation would enable the prolonged release of rPN
when administered intrapericardially. To test whether Gelfoam
disks become encapsulated within fibrin hydrogels in the absence
of severe bleeding, we implanted pre-swollen Gelfoam disks (in
PBS) into the peritoneum of mice. Animals were sacrificed after
2 hrs and 7 days, the devices were recovered, and histological
analysis was performed (Figure 1A). Hematoxylin and eosin
(H&E) staining revealed that Gelfoam induced a minimal
inflammatory response at both time points (Figure 1B), which
is in agreement with previously reported studies [23–26]. Acid
Fuchsin Orange-G (AFOG) staining revealed the presence of a
dense fibrin network that interpenetrated the Gelfoam porous
network (Figure 1B). The presence of fibrin was confirmed by
immunofluorecent staining on sections with an antibody against
fibrin(ogen) (Figure 1B). It is important to note that Gelfoam
disks were not encased within a fibrotic capsule (lack of blue
staining in AFOG), which is in agreement with previous studies
[24–26] and suggests that Gelfoam disks do not induce a foreign
body response.
Fibrin prolongs rPN release from Gelfoam scaffolds In
Vitro and In Vivo
To quantify the release of rPN from Gelfoam, we labeled rPN
with the fluorophore Alexa Fluor 488 (Figure S1). The release
profile of fluorescently-labeled rPN (rPN-AF488) from Gelfoam
was assessed in vitro (Figure 2A). rPN-AF488 was rapidly released
from Gelfoam disks. Interpolation of the release prolife indicates
that the time required for 50 and 90% release (t50 and t90)i s,0.5
and ,2 hrs, respectively (Table 1). After 2 days, the rate of rPN-
AF488 release from Gelfoam remained constant, at which point
we added trypsin to degrade the gels to confirm that all the rPN
had been released from the Gelfoam. Interestingly, approximately
10% of the rPN initially loaded was still detected within the
degraded gels, suggesting that either electrostatic and/or hydro-
phobic interactions may play a role in determining the release
profile.
We evaluated the ability of fibrin to prolong the release of rPN-
AF488 from Gelfoam disks, in vitro (Figure 2A). To test this, we
encapsulated Gelfoam disks loaded with rPN-AF488 within a
fibrin hydrogel and incubated them in PBS at 4uC for 2 days. rPN-
AF488 release from the composite hydrogels exhibited a smaller
burst release compared to Gelfoam alone (25% vs 50% within the
first 30 min, respectively) and a more sustained release of rPN-
AF488 over the time period studied. These data suggest that
Gelfoam’s innate ability to induce fibrin deposition may provide a
unique mechanism to prolong the in vivo release of rPN from
Gelfoam matrices.
To evaluate the release profile in vivo, Gelfoam disks loaded with
rPN-AF488 were implanted within the peritoneum of mice [27].
After 0.5, 2, 20, 48, 96, and 168 hrs, Gelfoam disks were retrieved
and either degraded to determine the amount of rPN-AF488
released or processed for histological analysis. Following a minimal
burst release within the first hour (,26%), rPN displayed a
sustained release from Gelfoam disks over the time period studied
(Figure 2B). Interpolation from the graph indicates that the t50
and t90 values are 15 and 50 hrs, respectively (Table 1). It is
important to note that these values are significantly higher than
those obtained from the in vitro release experiments from Gelfoam
alone (t50 and t90 values of 0.5 and 2 hrs, respectively; Table 1),
indicating the fibrin is able to retard rPN release. Histological
analysis of explanted disks, taken 2 hrs and 7 days post
implantation, was characterized by mild inflammation and
significant fibrin deposition within the interstitial pores of Gelfoam
disks (Figure 2C).
To determine if fibrin deposition contributed to the observed
release in vivo, we inhibited fibrin formation with heparin and
performed similar release studies with Gelfoam disks preloaded
with rPN-AF488 (Figure 2B, inset). Gelfoam disks treated with
heparin rapidly released rPN-AF488 within 1 hour after implan-
tation. This result is similar to the release rates of rPN-AF488 from
Gelfoam disks alone in vitro and suggests that thrombosis formation
plays a critical role in prolonging the release of rPN from Gelfoam
matrices.
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To determine if rPN can diffuse into the myocardium after
intrapericardial injection we performed ex vivo diffusion experi-
ments using mouse hearts. To evaluate the diffusibility of rPN
before and after injury, fluorescently-labeled rPN was loaded onto
Gelfoam disks, and glued to the left ventricular surface of normal
and cryo-injured hearts. Subsequent histological analysis revealed
that rPN diffusion through healthy myocardium was minimal
(,216 mm), compared to its diffusion through cryo-injured cardiac
tissue (,830 mm, P,0.0001, Figure 3) after 2 hours at 37uC and
5% CO2. These results suggest that intrapericardial administration
is a highly effective method to deliver rPN specifically to the
infarcted region of the myocardium.
Gelfoam disks become encapsulated within a fibrin
matrix after injection into the pericardial cavity of pigs
In order to verify that a similar clotting mechanism occurred in
the pericardial cavity of large mammals, we injected Gelfoam
loaded with or without rPN into the pericardial cavity of Yorkshire
pigs following occlusion of the left anterior descending artery
(Figure 4). One or twelve weeks later, animals were euthanized
and a gross examination of the heart was conducted. One week
after implantation, we observed a similar response as was seen
when Gelfoam was implanted within the peritoneum of mice
(Figure 5A–D). No evidence of the Gelfoam disk was present
twelve weeks after implantation. To confirm that the material
encasing the Gelfoam was similar to what we observed in the
peritoneum of mice (i.e. fibrin), we stained sections with H&E
(Figure 5B), AFOG (Figure 5D), and antibodies against
fibin(ogen) (Figure 5C). As observed previously in the mouse
peritoneum, implantation of Gelfoam within the pericardial cavity
is characterized by a mild inflammatory response, significant fibrin
deposition, and a lack of a fibrotic capsule.
Extended delivery of rPN increases cardiomyocyte cell
cycle activity and angiogenesis in the infarct border zone
We have previously demonstrated in rats that rPN increases the
cell cycle activity of cardiomyocytes and the degree of vascular-
ization within the border zone after MI [1]. We utilized the known
biological activity of rPN to confirm that Gelfoam-induced fibrin
hydrogels could provide a sustained release of rPN to the
myocardium following intrapericardial administration in a swine
model of myocardial infarction. We first visualized the cell cycle
activity by staining tissue sections with antibodies against PCNA
and Ki67 (Figure 6A–D). Quantification revealed that rPN-
treated animals had 0.5060.3 PCNA-positive cardiomyocytes per
millimeter squared one week after administration, a 5-fold increase
over control animals (P,0.01, Figure 6B). To verify that the
detected cell cycle activity was located in cardiomyocytes,
cardiomyocytes were isolated from the border zone by enzymatic
digestion and stained with an antibody against Ki67 (Figure 6D).
Ki67 is a well accepted marker of progression through the cell
cycle. As such, we utilized Ki67 to enhance the probability of
Figure 1. Gelfoam hydrogels explanted from the peritoneal cavity of mice are encased within a fibrin matrix. (A) Photomicrographs of
explanted Gelfoam sponges at various time points. (B) Explanted Gelfoam sponges were characterized by immunohistochemistry and
immunofluorescence. Sections were stained with hemotoxylin and eosin (H&E), fibrin(ogen), and acid fuschin orange –G (AFOG). Green arrows
indicate fibrin deposition within the Gelfoam sponge. Scale bars, (A) 10 mm; (B) 50 mm.
doi:10.1371/journal.pone.0036788.g001
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tissue we had for the analysis (as opposed to staining for antibodies
against PCNA or H3P which is much more selective for
cardiomyocyte progressing through either S- or M-phase, respec-
tively). The results indicated that large rod-shaped cardiomyocytes
were in the cell cycle (Figure 6D). We then stained tissue sections
with an antibody against phosphorylated histone H3 at S10 (H3P)
to visualize cells in mitosis (Figure 6E–F). Quantification of H3P-
positive cardiomyocytes on sections revealed that rPN-treated
animals had 0.1360.01 H3P-positive cardiomyocytes per milli-
meter squared one week after administration, a 6.5–fold increase
over controls (P,0.001, Figure 6G). Furthermore, our results
demonstrate that rPN did not induce cell cycle activity in non-
cardiomyocytes (Figure S2). To further demonstrate that
Gelfoam-induced fibrin hydrogels were critical for the sustained
release of rPN to the myocardium, rPN alone was injected into the
pericardial space of pigs after myocardial infarction. Quantifica-
tion of H3P-positive cardiomyocytes on sections revealed that
Gelfoam disks loaded with rPN had a 2.2-fold increase in the
number of H3P-positive cardiomyocytes compared to pigs injected
with rPN alone (P,0.05, Figure 6H), indicating that Gelfoam is
required for a maximal exposure.
The degree of vascularization, twelve weeks after MI, was
visualized by staining tissue sections with antibodies against CD31
to identify the endothelial layer of blood vessels and with
myomesin to demarcate cardiomyocytes (Figure 7A–B). Quan-
tification revealed a higher number of CD31 positive vessels within
the border zone in rPN-treated animals relative to controls
(Figure 7C, P,0.05). Collectively, these data demonstrate that
Figure 2. Fibrin encased Gelfoam hydrogels prolong rPN release In Vitro and In Vivo. (A) In vitro release kinetics of fluorescently-labeled
rPN (rPN-AF488) from Gelfoam and Gelfoam-Fibrin composite hydrogels in PBS at 4uC. (B) In vivo release kinetics of rPN-AF488 from Gelfoam and
Gelfoam/Heparin hydrogels implanted within the peritoneal cavity of mice. (C) Gelfoam sponges loaded with rPN –AF488 were explanted and
characterized by immunohistochemistry and immunofluorescence. Sections were stained with hemotoxylin and eosin (H&E), fibrin(ogen), and acid
fuschin orange –G (AFOG). Green arrows indicate fibrin deposition within the Gelfoam sponge. Scale bars, 50 mm.
doi:10.1371/journal.pone.0036788.g002
Table 1. Release Rates.
Gelfoam-rPN Device t50 (hours) t90 (hours)
In vitro 0.50 2.00
In vivo 15.00 50.00
In Vitro and In Vivo release rates from Gelfoam hydrogels.
doi:10.1371/journal.pone.0036788.t001
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the sustained release of rPN to the myocardium after MI.
rPN does not alter the fibrotic or inflammatory response
The periostin gene plays a role in the recruitment of fibroblasts
to the MI region and in the formation of scar tissue [8,9]. To
evaluate if rPN had an effect on myocardial fibrosis we stained
tissue sections from the MI border zone twelve weeks after
administration of therapy with acid fuchsin orange-G (AFOG,
Figure S3). The degree of fibrosis was quantified using two
independent techniques. First, we imaged the sections using light
microscopy followed by thresholding of the fibrotic areas (stained
blue) relative to the myocardial area (stained deep red), which
showed no difference between the groups (Figure S3B). Second, a
pathologist (R.P.) scored the degree of fibrosis on AFOG-stained
sections in a blinded manner, using a semi-quantitative scale and
found it to be similar between groups (Figures S3C). To further
investigate the possibility that rPN administration may have an
effect on fibroblast proliferation, we quantified the number of non-
myocytes undergoing mitosis in the border zone after one week of
treatment (Figure S2B). rPN did not affect mitotic activity of non-
myocytes, consistent with recent findings in periostin knockout
mice [28]. The results of these two analyses of fibrosis demonstrate
that administration of rPN peptide does not alter myocardial
fibrosis after MI, which is in agreement with our previous
observations [1] and other studies [8,9,28].
The periostin gene has also been reported to influence reactive
inflammation [29–31]. Thus, we assessed if administration of rPN
has an effect on myocardial inflammation. We performed
histological analyses at one week after treatment with either rPN
or control. The degree of inflammation within the MI border zone
was determined in a blinded manner on a semi-quantitative scale
by a pathologist (R.P.). The results showed no difference in the
Figure 3. rPN readily diffuses into damaged myocardium. (A–B) Cross-sectional photomicrographs and pixel intensity profiles of rPN-AF488
diffusion through non-infarcted (A) and infarcted (B) mouse hearts. (C) Photomicrograph and pixel intensity prolife for cryo-injured heart only. (D)
Quantification reveals that rPN readily diffuses through injured myocardium but not healthy intact muscle. Red arrows demarcate the epicardial
surface and white arrows represent Gelfoam loaded with rPN-AF488. Analysis was performed 2 hrs after cryo-injury. The mean 6 SEM of 6
independent pixel intensity profiles is provided in the graphs.
doi:10.1371/journal.pone.0036788.g003
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rPN peptide (P,0.05, Figure S3D).
Discussion
Identification of novel factors that regulate myocardial regen-
eration is an exciting new paradigm in cardiac biology [5]. Our
laboratory has recently identified two extracellular factors that
have the ability to enhance cardiac function when administered
after MI [1,3]. Given the long time course required for myocardial
regeneration to occur, most preclinical interventions employ
repeated factor delivery to maintain the therapeutically required
dose [1,3,32–35]. However, this is not clinically practical and often
results in poor myocardial uptake and high systemic recirculation.
We hypothesized that the translational and clinical potential of
pharmaceutical-based therapies would be greatly enhanced by
intrapericardial administration of FDA-approved drug-eluting
biomaterials. Intrapericardial administration of growth factors
alone was previously shown to increase myocardial retention while
minimizing uptake by non-target organs [13]. We hypothesized
that encapsulation of factors within hydrogels would potentially
enable the prolonged release of factors to the myocardium, while
further enhancing the retention and bioactivity of rPN, by
minimizing lymphatic drainage and proteolytic degradation within
the pericardial space.
We chose to encapsulate rPN within Gelfoam disks for several
reasons. First, these devices are FDA approved, which greatly
enhances the clinical applicability of the proposed method. In fact,
a recent pre-clinical study has shown that intrapericardial
administration of Gelfoam into the pericardial space of pigs is
both feasible and safe [16]. Second, Gelfoam is able to absorb and
hold large amounts of fluid within its pores, which provides a
simple and efficient method for loading the rPN prior to
implantation. Also, Gelfoam disks have been used previously as
drug delivery vehicles. It is interesting to note that studies have
Figure 4. Myocardial infarction timeline and strategy for targeted delivery. (A) Experimental design for the delivery of rPN in a swine model
of myocardial infarction (MI). (B) Schematic illustration of the intrapericardial delivery of Gelfoam/rPN system and our strategy for tissue collection.
doi:10.1371/journal.pone.0036788.g004
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glycol or collagen are required to prolong the release of drugs,
such as pilocarpine and basic fibroblast growth factor (bFGF),
from Gelfoam disks [17,22]. In vivo implantation of Gelfoam is
known to induce the formation of fibrin-rich matrices without
triggering significant inflammatory or fibrotic responses. We
hypothesized that this spontaneous in vivo deposition of fibrin
within the interstitial sites of Gelfoam could be used as a natural
retardant to prolong rPN release, increase rPN bioactivity, and
decrease non-specific uptake of rPN by non-target organs.
To examine the role of fibrin deposition on the release kinetics
of rPN from Gelfoam disks, we performed both in vitro and in vivo
drug release experiments. The in vitro release profile of rPN from
Gelfoam disks alone was very rapid compared to rPN release from
Gelfoam-fibrin composite hydrogels. These results suggest that
fibrin deposition within the interstitial sites of Gelfoam disks is able
to effectively modulate rPN release. We performed similar in vivo
release experiments within the peritoneum of mice. Peritoneal and
pericardial fluids have similar compositions, as both are ultra
filtrates of the plasma [36]. The in vivo release profile of rPN from
Gelfoam was much slower than its in vitro release from Gelfoam
alone. To determine if fibrin deposition played a critical role in
modulating the release kinetics, we implanted Gelfoam disks
loaded with heparin and rPN. Heparin is known to inhibit fibrin
formation by activation of antithrombin and factor Xa [37]. rPN
release from heparin-treated Gelfoam disks was rapid, with
approximately 100% release occurring within 1 hr of implanta-
tion. These data strongly suggest that the fibrin network formation
triggered by in vivo administration of Gelfoam is critical for the
extended release of rPN from these devices.
The in vivo applicability of our approach was tested by injecting
our delivery systems into the pericardial space of pigs two days
after MI. Histological analysis one week after injection revealed
minimal inflammation, no evidence of a fibrotic capsule, and
extensive fibrin(ogen) and fibrin deposition on the surface of the
Gelfoam as well as within the interstitial sites, respectively. These
results are similar to those observed from Gelfoam disks explanted
from the peritoneal cavity of mice, and suggests that Gelfoam-
induced fibrin hydrogels are present after intrapericardial admin-
istration of Gelfoam disks. We quantified PCNA and H3P-positive
cardiomyocytes as well as CD31-positive vessels in order to
characterize the bioactivity and the in vivo release of rPN from
Gelfoam-induced fibrin hydrogels. Our results clearly indicate that
Gelfoam-induced fibrin hydrogels provide a sustained release of
rPN for an extended period of time. This correlates with our in vivo
release profile, in which rPN was shown to be released from the
Gelfoam-induced fibrin hydrogels over a period of seven days.
This data also suggests that Gelfoam disks injected into the
pericardial space are not degraded at an accelerated rate (i.e. they
are present 7 days after implantation). It is also important to note
that the therapeutic effect of rPN encapsulated within Gelfoam-
induced fibrin hydrogels is superior to rPN alone. Injection of rPN
into the pericardial space is most likely eliminated by either
lymphatic drainage and/or proteolytic cleavage; whereas encap-
sulation within the Gelfoam hydrogels retains the drug within the
cavity and may preserve its bioactivity [14].
Previous studies have shown that the effects of intrapericardial
administration are limited to the epicardial surface of the heart
[13]. While this did not represent a limitation in the current study,
it may be a limiting factor for certain conditions, such as
endocardial infarctions, which require the therapeutic to diffuse
through the bulk of the myocardium. Also, the results from this
study do not permit one to draw conclusions about rPN’s ability to
stimulate cardiomyocyte proliferation or its effect on cardiac
function. Swine cardiomyocytes are known to have multiple nuclei
(up to 32 per cardiomyocyte) and stimulation of cell cycle activity
does not necessarily correlate with cardiomyocyte division.
Intrapericardial administration of drug eluting biomaterials is a
novel, clinically attractive, and effective method for the targeted
delivery of therapeutics to the myocardium after MI. We utilized
the body’s innate immune response (i.e. thrombus formation) to
Gelfoam implantation to facilitate the prolonged release of rPN to
the myocardium. The approach presented here utilizes established
clinical procedures and FDA approved medical devices to enhance
factor retention and bioactivity within the pericardial cavity and to
prolong the biological effect in vivo. This strategy may serve as a
platform for rapid testing of new pharmaceuticals that have to be
targeted to the heart. In addition, our findings may inspire the
future development of advanced biomaterials that enable, for
example, the spatio-temporal delivery of multiple factors over
various time scales to mediate cardiac injury and to induce
myocardial regeneration.
Materials and Methods
Ethics Statement
All experiments in this study were conducted in accordance with
the guidelines established by the Institutional Animal Care and
Use Committee at Mount Sinai School of Medicine and
Children’s Hospital Boston and the American Association for
Accreditation of Laboratory Animal Care and were approved by
the Institutional Animal Care and Use Committee at MSSM and
CHB. All efforts were made to minimize any pain and suffering
felt by the animals.
Figure 5. Gelfoam gels loaded with rPN become encased with
fibrin-rich hydrogels after intrapericardial injection in pigs. (A)
Cross-sectional photomicrograph of the explanted Gelfoam disk 7 days
after implantation. (B–D) Explanted Gelfoam disks were characterize d
with hematoxylin and eosin (H&E, B), immunofluorescent staining for
fibrinogen (C) acid-fuschin orange-G (AFOG, D). Green arrows indicate
fibrin deposition. Scale bars, (A) 20 mm; (B–D) 50 mm.
doi:10.1371/journal.pone.0036788.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36788Figure 6. Gelfoam loaded with rPN increases cardiomyocyte cell cycle activity after MI. (A–D) Visualization and quantification of cell cycle
activity in tissue sections and in isolated cardiomyocytes from animals treated with rPN, respectively. (E–F) Determination of cardiomyocyte mitosis
by visualization of H3P positive cardiomyocyte nuclei. A series of yz reconstructions is shown to the right of the micrograph. (G) Quantification of
cardiomyocyte mitosis after 1 wk and 12 wks of treatment. (H) Quantification of the effect of administering rPN adsorbed onto Gelfoam versus
administration of rPN alone on cardiomyocyte mitosis. H3P, phosphorylated histone H3 (S10); Ctr, hearts receiving Gelfoam with PBS; rPN, hearts
receiving Gelfoam with periostin peptide; n is the number of animals per group. Scale bars, 100 mm.
doi:10.1371/journal.pone.0036788.g006
Figure 7. Delivery of rPN/Gelfoam system increased vascularization in the border zone. (A, B) Visualization of CD31 positive vessels within
the border zone in both control (A) and rPN (B) treated animals. (C) Quantification of vessel density in the border zone. Ctr, hearts receiving Gelfoam
with PBS; rPN, hearts receiving Gelfoam with periostin peptide; n is the number of animals per group. Scale bars, 100 mm.
doi:10.1371/journal.pone.0036788.g007
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Gelfoam (Pfizer) was cut into disks using a standard 6 mm
biopsy punch (6 mm62 mm). Loading was accomplished by
application of an aliquot of rPN-AF488 (,2 mg) to each Gelfoam
disk followed by incubation at 4uC for 12 hrs. The volume added
to each Gelfoam disk was much less than the maximal absorbable
volume to ensure that the applied dose was completely loaded
within each gel. Loading was determined by quantifying the
amount of fluorescence in solution after degradation of at least 3
individual disks by enzymatic treatment (trypsin). For release
studies, the Gelfoam disks, loaded with or without rPN-AF488,
were placed within the wells of a 96-well plate containing 50 mLo f
phosphate-buffered saline (PBS). The plate was covered and
placed at 4uC with intermittent agitation. To determine the
fraction of rPN-AF488 released from the Gelfoam gels, the PBS
within each well was removed at various time points and replaced
with an equivalent volume of fresh buffer. The collected buffer was
then analyzed on a fluorescent plate reader (lex=494 nm,
lem=519 nm), and the amount (in mg) of rPN-AF488 released
was calculated by interpolation from a standard fluorescent
calibration curve. At the end of the experiment, all Gelfoam disks
were degraded and the amount of retained rPN-AF488 was
determined. The cumulative release was calculated by summing
the amount of rPN-AF488 released over the various time intervals.
The percentage of cumulative rPN-AF488 released is reported as
the ratio of the cumulative release of rPN-AF488 (in mg) at any
point in time to the initial amount of rPN-AF488 (in mg) that had
been loaded.
Gelfoam disks encapsulated within fibrin gels were prepared as
follows. Gelfoam disks (6 mm62 mm) were pre-swollen in a stock
solution of thrombin (25 U/mL) for 30 mins at room temperature.
The disks were subsequently allowed to dry at 4uC for 3 days. rPN-
AF488 (,2 mg) was loaded into individual thrombin-loaded
Gelfoam disks by incubation at RT for 30 min. Again, the
volumes added were much smaller than the maximum swelling
volume, which ensured that the applied dose was completely
loaded within each gel. The thrombin/rPN-AF488 loaded
Gelfoam disks were then placed into a solution of fibrinogen
(25 mL, 3.3 mg/mL solution) for 20 mins at 37uC. The amount of
rPN-AF488 loaded was determined by enzymatic degradation of
at least 3 Gelfoam-fibrin hydrogels. The percentage release of
rPN-AF488 was determined as described above.
In Vivo release of rPN-AF488 from Gelfoam hydrogels
Gelfoam disks (6 mm62 mm) were pre-swollen in a stock
solution of heparin (5000 U/mL) for 30 min at room temperature.
The disks were subsequently allowed to dry at 4uC for 3 days. rPN-
AF488 (,2 mg) was allowed to absorb into Gelfoam disks, loaded
with or without heparin, for 30 min at room temperature prior to
implantation. The Gelfoam disks were subsequently implanted
into the peritoneal cavity of healthy adult mice (1 disk/animal; 3
animals per time point). Gelfoam disks loaded with heparin and
rPN-AF488 were extracted after 30 mins, 1 hr, and 2 hrs; whereas
Gelfoam disks loaded with rPN-AF488 only were explanted after
30 mins, 1 hr, 20 hrs, 48 hrs, 96 hrs, and 168 hrs. The animals
were euthanized, the disks retrieved, and they were degraded in
Eppendorf vials via treatment with trypsin (25 mL, 3 mg/ml, 37uC
for 20 min). Vials were spun down at 14,0006g, the supernatant
was added to a black, 96-well flat bottom plate, and the
fluorescence was quantified using a standard fluorescent plate
reader. The amount of rPN-AF488 loaded was determined by
enzymatic degradation of at least 3 Gelfoam-heparin disks (not
implanted). The amount of rPN-AF488 retained within the disk
(mg) was determined as described above. The percent rPN-AF488
released was calculated according to the following equation:
% Release~
Xi{Xf
Xi
|100 %
where Xf is the amount of rPN-AF488 remaining in the Gelfoam
disk at time t and Xi is the amount of rPN-AF488 initially loaded.
Diffusion of rPN-AF488 into the myocardium
Diffusion of rPN into the myocardium was evaluated ex vivo
using fluorescently-labeled rPN. Adult mouse hearts (CB57/SL6)
were isolated using standard techniques and immediately placed in
ice cold PBS to flush out the ventricles. Hearts were glued to the
bottom of Petri dishes (35 mm) with the left ventricle pointing up.
Hearts then received no injury/Gelfoam/rPN-AF488 (control),
cryo injury/Gelfoam/rPN-AF488 (3 independent 5 second expo-
sures over the same region using a 3 mm probe) or cryo injury
only (same exposure). Gelfoam sponges loaded with rPN-AF488
(0.84 mg) were glued to the surface of the heart. In the case of the
cryo-injured hearts, care was taken to ensure that the Gelfoam was
directly over the injured area. Culture media (containing 10%
FBS) was then added to the Petri dishes and the plates incubated at
37uC in 5% CO2 for 2 hours. The hearts were then carefully
released from the dishes using a razor blade, rinsed in ice-cold
PBS, and immediately embedded in OCT. Detailed information
on the histological analysis and quantification of rPN-488 diffusion
is provided in the File S1.
Myocardial infarction (MI) model, delivery of rPN, and
sample collection
All manipulations were approved by the IACUC and performed
at Mount Sinai School of Medicine (MSSM). In order to enhance
the clinical applicability of this delivery system, Gelfoam disks were
milled using a standard bone rasp, which enabled administration
via injection through standard catheters [16]. Myocardial infarc-
tions (MI) were created in 20 kg female Yorkshire pigs by
placement of a platinum coil within the left anterior descending
coronary artery (MSSM). Two days after infarct generation, the
cardiac function was assessed (i.e. ejection fraction, peak ejection
rate, peak filling rate, cardiac index, and dPdt/P) and animals that
had similar values (i.e. within 20%) were used in the study. The
animals were randomly assigned to control (6 animals) or test
groups (7 animals). Animals underwent a thoracotomy to expose
the pericardium. Gelfoam disks loaded with either saline (7 mL;
control group) or rPN (0.1 mg/mL; 0.7 mg per pig; treatment
group) were injected into the pericardial cavity (Figure 4B). The
pericardium was sutured to prevent leakage into the thoracic
cavity. Pigs were euthanized one and twelve weeks after
implantation of the delivery system. Samples from the MI border
zone, from within the MI, and from the non-infarcted inferior wall
were sectioned into 3 zones (epicardium, myocardium, and
endocardium), snap frozen or placed in OCT and subsequently
shipped to Children’s Hospital Boston.
Immunofluorescence
Heart samples were embedded in optimal cutting temperature
compound (OCT) and placed at 280uC. We prepared cryosec-
tions (14 mm thick), fixed them in 10% buffered formalin,
permeabilized with 0.5% NP-40 dissolved in phosphate buffered
saline (PBS), and blocked with goat serum (5%, Sigma). Sections
were subsequently treated with primary antibodies against PCNA
(Abcam), Ki67 (Abcam) and phosphorylated histone-3 (S10,
Millipore) to visualize cardiomyocytes in the cell cycle, troponin
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cyte-specific proteins in the contractile apparatus, CD31 (Abcam)
to visualize the presence of blood vessels, and fibrinogen to
visualize the presence of fibrin/fibrinogen (Ventana Medical
Systems) within Gelfoam disks. Sections were subsequently treated
with secondary antibodies conjugated to either Alexa 488 or 594.
Nuclei were stained with DAPI. To quantify the number of PCNA
and H3P positive cardiomyocyte nuclei per millimeter squared of
myocardium we analyzed 3 different hearts per group. For each
heart we randomly selected and counted the number of PCNA or
H3P positive cardiomyocyte events from 6 slides containing 3–4
sections per slide (only 1 section/slide was quantified). The area of
each tissue section was determined using the method of point
counts [38] and the ratio of PCNA or H3P positive cardiomyocyte
nuclei per area of myocardium was calculated. Quantification of
the number of CD31 positive blood vessels was accomplished by
acquiring multiple (,10–15) fluorescent images from each tissue
section, using a random systematic approach. The number of
vessels per image was quantified using ImageJ and divided by the
area of the field of view. Images were acquired using an Olympus
IX-81 epifluorescence microscope with LUCPLFL 406 and
UPLFL 106 lenses equipped with a Hamamatsu CM CCD
camera. Quantification of PCNA and H3P data was indepen-
dently validated by BDP and SA.
Histology
Gelfoam disks explanted from the peritoneal cavity of mice were
harvested and immediately fixed in 3.7% formaldehyde overnight.
Samples were either frozen at 280uC or embedded in optimal
cutting temperature. Gelfoam disks were cut into 10 mm sections
and re-fixed in 10% buffered formalin. Gelfoam disks explanted
from the pericardial cavity of pigs were harvested and either
embedded in OCT compound or snap frozen in liquid nitrogen.
Samples were cut into 14 mm sections and fixed in 10% buffered
formalin. Sections were stained with hematoxylin and eosin to
visualize inflammation and acid fuchsin orange-G (AFOG) to
visualize fibrin deposition. Images were acquired using a Zeiss
Axioplan 2 epifluorescence microscope with Plan-Neofluar 106
and 406lenses equipped with a Zeiss Axiocam CCD camera.
Isolation of cardiomyocytes
Frozen samples of myocardial tissue were brought to room
temperature and immediately fixed in 10% buffered formalin. The
tissue was subsequently incubated with collagenase D (2.4 mg/
mL, Roche) and B (1.8 mg/mL, Roche) for 24 hours at 37uC with
constant agitation. The supernatant was collected and spun down
to yield the isolated cardiomyocytes. This procedure was repeated
until no more cardiomyocytes were dissociated from the tissue.
The cardiomyocytes were stained for the presence of cell cycle
markers as described in the Immunofluorescence section. The
efficiency of the isolation procedure was 91.363% (by mass) and
the percent intactness was 92.460.4% (determined by cadherin
staining). The percents are given as mean 6 SEM, n=8 hearts.
Statistical Analysis
One-way ANOVA was used to analyze myocardial fibrosis and
cell cycle data. Two-tailed Student’s t-test was used for vascular
density and non-cardiomyocyte proliferation analyses. All mea-
surements were reported as the mean 6 SEM. Significance was
accepted at p,0.05. Number of animals in pig experiments: 6
control (Gelfoam only) and 7 treatment (Gelfoam/rPN). Number
of animals in mouse experiments: 3 control (Gelfoam only) and 3
treatment (Gelfoam/rPN-AF488).
Supporting Information
File S1 Supplemental information is available for the following:
synthesis and characterization of rPN-AF488, quantification of
non-myocyte cell cycle activity, and quantification of myocardial
fibrosis and inflammation.
(DOCX)
Figure S1 Synthesis and characterization of rPN-AF488.
(A) Schematic comparing the protein structure of the type 1
variant of human periostin with the recombinant truncated
peptide used in this study. The recombinant PN peptide is
truncated from amino acid 1–22 and from 672–836. (B) Schematic
representation of the bio-conjugation technique used to fluores-
cently-label rPN with Alexa Fluor 488. (C) SDS-PAGE analysis of
rPN-AF488 and rPN (control).
(TIF)
Figure S2 Administration of Gelfoam loaded with rPN
does not stimulate non-cardiomyocyte cell cycle activity
(A) Photomicrograph of a H3P positive non-cardiomyocyte within
the infarct border zone. (B) Quantification of non-cardiomyocyte
mitosis after 1 wk of treatment. Ctr., control hearts receiving
Gelfoam with buffer; rPN, hearts receiving Gelfoam with periostin
peptide; n is the number of animals per group. Scale bars, 100 mm.
(TIF)
Figure S3 Delivery of Gelfoam loaded with rPN does not
alter myocardial fibrosis or inflammation in the infarct
border zone. (A–C) Visualization and quantification of myocar-
dial fibrosis from tissue sections stained with acid fuchsin orange G
(AFOG). Fibrosis was determined both quantitatively using an
image analysis software (B) and semi-quantitatively by a
pathologist in a blinded manner (C). (D) Visualization of
myocardial inflammation using Hematoxylin and eosin staining
(H&E). (E) Quantification of myocardial inflammation was
performed in a blinded manner by a pathologist. Ctr., control
hearts receiving Gelfoam with buffer; rPN, hearts receiving
Gelfoam with periostin peptide; n is the number of animals per
group. Scale bars, 100 mm.
(TIF)
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